JPH10503487A - 疼痛寛解剤としての芳香族アミノエーテル - Google Patents
疼痛寛解剤としての芳香族アミノエーテルInfo
- Publication number
- JPH10503487A JPH10503487A JP8505573A JP50557396A JPH10503487A JP H10503487 A JPH10503487 A JP H10503487A JP 8505573 A JP8505573 A JP 8505573A JP 50557396 A JP50557396 A JP 50557396A JP H10503487 A JPH10503487 A JP H10503487A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- benzyloxy
- ethylamino
- bromobenzyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/41—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/13—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式I: [式中: Aは、場合により置換された次のものであり: 少なくとも2つの隣接する環炭素原子を有するフェニル、ナフチル、ピリジル 、ピラジニル、ピリダジニル、ピリミジル、チエニル、チアゾリル、オキサゾリ ル、チアジアゾリル又は式: (ここで、Eは窒素又はCHであり、Fは窒素又はCHであり、Gはイオウ又は 酸素であり、かつHは窒素又はCHである)の2環式環系; 但し、−CH(R3)N(R2)B−R1及び−OCH(R4)−D架橋基は、相 互に1,2関係で、環炭素原子上に位置し、かつ−OCHR4−架橋基に対して オルトに(従って、−CHR3NR2−架橋基に対し て3−位に)位置する環原子は、置換されてなく; Bは、場合により置換された次のものであり: フェニル、ピリジル、チアゾリル、オキサゾリル、チエニル、チアジアゾリル 、イソオキサゾール、ピラゾール、フリル、ピロリル、イミダゾリル、ピラジニ ル、ピリダジニル、ピリミジル、ピリドン、ピリミドン、ピラジノン又はピリダ ジノン; Dは、場合により置換されたピリジル、ピラジニル、ピリミジニル、ピリダジ ニル、ピロリル、チエニル、フリル、イミダゾリル、ピラゾリル、チアゾリル、 イソチアゾリル、オキサゾリル、イソオキサゾリル又はフェニルであり; R1は、環B上に、6員環では、−CH(R3)N(R2)−架橋基と1,3又 は1,4関係に、かつ5員環では、−CH(R3)N(R2)−架橋基と1,3− 関係に位置し、かつカルボキシ、カルボキシC1〜C3アルキル、テトラゾリル、 テトラゾリルC1〜C3アルキル、テトロン酸、ヒドロキサム酸、スルホン酸であ るか、又はR1は、式(IIA)、(IIB)又は(IIC): (ここで、XはCH又は窒素であり、Yは酸素又はイ オウであり、Y1は酸素又はNHであり、かつZは、CH2、NH又は酸素である )であるが、但し、1個を上回る環酸素は存在せず、かつ少なくとも2つの環ヘ テロ原子が存在するか、;又はR1は、式:−CONRaRal又は−C1〜C3アル キルCONRaRal(ここで、Raは、水素、C1〜C6−アルキル、C3〜C7−シ クロアルキル、C3〜C7−シクロアルキルC1〜C3アルキル、C5〜C7シクロア ルケニル又はC5〜C7シクロアルケニルC1〜C3アルキルであり、かつRalは、 水素、ヒドロキシ又は場合により置換された:C1〜C10アルキル、C2〜C10ア ルケニル、C2〜C10アルキニル、C3〜C7シクロアルキル、C3〜C7シクロア ルキルC1〜C6アルキル、C3〜C7シクロアルキルC2〜C6アルケニル、C3〜 C7シクロアルキルC2〜C6アルキニル、C5〜C7シクロアルケニル、C3〜C7 シクロアルケニルC1〜C6アルキル、C5〜C7シクロアルケニルC2〜C6アルケ ニル、C5〜C7シクロアルケニルC2〜C6アルキニル、5−員の又は6−員のヘ テロアリール、5−員の又は6−員のヘテロアリールC1〜C6−アルキル、5− 員の又は6−員の飽和又は部分飽和ヘテロシクリル又は5−員の又は6−員の飽 和又は部分飽和ヘテロシクリルC1〜C6アルキルであるか;又はここで、Ra及 びRalは、それらが結合している(NRaRal)アミド窒素と一緒になって、ア ミノ酸基又はそれらのエステルを製造する)で あるか;又はR1は、式:−CONHSO2Rb又は−C1〜C3アルキルCONH SO2Rb(ここで、Rbは、場合により置換された;C1〜C10アルキル、C2〜 C10アルケニル、C2〜C10アルキニル、C3〜C7シクロアルキル、C3〜C7シ クロアルキルC1〜C6アルキル、C3〜C7シクロアルキルC2〜C6アルケニル、 C3〜C7シクロアルキルC2〜C6アルキニル、C5〜C7シクロアルケニル、C3 〜C7シクロアルケニルC1〜C6アルキル、C5〜C7シクロアルケニルC2〜C6 アルケニル、C5〜C7シクロアルケニルC2〜C6アルキニル、5−員の又は6− 員のヘテロアリール、5−員の又は6−員のヘテロイルアルC1〜C6−アルキル 、フェニル、フェニルC1〜C6アルキル、5−員の又は6−員の飽和又は部分飽 和ヘテロシクリル又は5−員の又は6−員の飽和又は部分飽和ヘテロシクリルC1 〜C6−アルキルである)であるか、又はR1は、式:−CONRaN(Rc)Rd又 は−C1〜C3アルキルCONRaN(Rc)Rd(ここで、Raは、前記と同様に定義 され、Rcは、水素又はC1〜C6アルキルであり、かつRdは、水素、ヒドロキシ 又は場合により置換された:C1〜C10アルキル、C2〜C10アルケニル、C2〜 C10アルキニル、C3〜C7シクロアルキル、C3〜C7シクロアルキルC1〜C6ア ルキル、C3〜C7シクロアルキルC2〜C6アルケニル、C3〜C7シクロアルキル C2〜C6アルキニル、C5〜C7シクロアルケニ ル、C5〜C7シクロアルケニルC1〜C6アルキル、C5〜C7シクロアルケニルC2 〜C6アルケニル、C5〜C7シクロアルケニルC2〜C6アルキニル、5−員の又 は6−員のヘテロアリール、5−員の又は6−員のヘテロアリールC1〜C6−ア ルキル、5−員の又は6−員の飽和又は部分飽和ヘテロシクリル、5−員の又は 6−員の飽和又は部分飽和ヘテロシクリルC1〜C6アルキルであるか、又はRc 及びRdは、それらに結合している窒素原子と一緒になって、4〜8−員の飽和 又は部分飽和複素環を形成するか、又はアミノ酸基又はそのエステルを形成する )であり; R2は、水素、C1〜C6アルキル(場合により、ヒドロキシ、シアノ、ニトロ 、アミノ、ハロ、C1〜C4アルカノイル、C1〜C4−アルコキシ又はトリフルオ ロメチルにより置換されている)C2〜C6アルケニル、C2〜C6アルキニル、C3 〜C6−シクロアルキル、C3〜C6−シクロアルキルC1〜C3アルキル、C3〜 C6−シクロアルキルC2〜C3アルケニル、C5〜C6シクロアルケニル、C3〜C6 シクロアルケニルC1〜C3アルキル、C5〜C6シクロアルケニルC2〜C3アル ケニル、フェニルC1〜C3アルキル又は5−員の又は6−員のヘテロアリールC1 〜C3アルキルであり; R3は、水素又はC1〜C4アルキルであり; R4は、水素又はC1〜C4アルキルである]の化合物 又はその、化学的に可能な場合には、−NR2のN −酸化物; 又は化学的に可能な場合には、イオウ含有環のS−酸化物; 又は薬剤的に容認可能な塩又は生体内で加水分解可能なエステル又はアミド。 2.式中のAが、場合により置換されたフェニル、ナフチル、チアジアゾリル 、チエニル、ピリジル又はピリミジルである、請求項1に記載の化合物。 3.式中のBが、場合により置換された:ピリジル、フェニル、チアゾリル、 チエニル、ピリダジニル、チアジアゾリル、イミダゾリル、ピラジニル、ピリミ ジル又はオキサゾリルである、請求項1又は2のいずれかに記載の化合物。 4.式中のR3が、水素又はメチルであり、かつR4が、水素である、請求項1 から3のいずれかに記載の化合物。 5.式中のDが、チエニル、フリル又はフェニルである、請求項1から4のい ずれかに記載の化合物。 6.式中のR2が、水素、エチル、アリル又は3−プロピニルである、請求項 1から5のいずれかに記載の化合物。 7.式中のAが、置換されていないか、又はハロ、トリフルオロメチル、ニト ロ、ヒドロキシ、アミノ、C1〜C4アルキルアミノ、ジC1〜C4アルキルアミノ 、シアノ、C1〜C6アルコキシ、S(O)pC1〜C6 アルキル(pは、0、1又は2である)、C1〜C6アルキル(場合により、ヒド ロキシ、アミノ、ハロ、ニトロ又はシアノにより置換)、S(O)pCF3(p= 0、1又は2)、カルバモイル、C1〜C4アルキルカルバモイル、ジ(C1〜C4 アルキル)カルバモイル、C2〜C6アルケニル、C2〜C6アルキニル、C2〜C4 アルケニルアミノ、N−C2〜C4アルケニル−N−C1〜C4アルキルアミノ、ジ −C2〜C4アルケニルアミノ、S(O)pC2〜C6アルケニル、C2〜C4アルケ ニルカルバモイル、N−C2〜C4アルケニル−N−アルキルアミノ、ジ−C2〜 C4アルケニルカルバモイル、C3〜C7シクロアルキル、C3〜C7シクロアルキ ルC1〜C3アルキル、C3〜C7シクロアルキルC2〜C3アルケニル、C5〜C7シ クロアルケニル、C5〜C7シクロアルケニルC1〜C3アルキル、C5〜C7シクロ アルケニルC2〜C3アルケニル、C5〜C7シクロアルケニルC2〜C3アルキニル 、C1〜C4アルコキシカルボニルアミノ、C1〜C4アルカノイルアミノ、C1〜 C4アルカノイル(N−C1〜C4アルキル)アミノ、C1〜C4アルカンスルホン アミド、ベンゼンスルホンアミド、アミノスルホニル、C1〜C4アルキルアミノ スルホニル、ジ(C1〜C4アルキル)アミノスルホニル、C1〜C4アルコキシカ ルボニル、C1〜C4アルカノイルオキシ、C1〜C6アルカノイル、ホルミルC1 〜C4アルキル、トリフルオロC1〜3アルキルスルホニ ル、ヒドロキシイミノC1〜C6アルキル、C1〜C4アルコキシイミノC1〜C6ア ルキルC1〜C6アルキルカルバモイルアミノ、オキサゾリル、ピリジル、チアゾ リル、ピリミジル、ピラジニル又はピリダジニルにより置換されている、請求項 1から6のいずれかに記載の化合物。 8.式中のBが、未置換であるか、又はアミノ、C1〜C4アルキルアミノ、ジ (C1〜C4アルキル)アミノ、ハロ、トリフルオロメチル、ニトロ、ヒドロキシ 、C1〜C6アルコキシ、C1〜C6アルキル、シアノ、−S(O)pC1〜C6アル キル(pは、0、1又は2である)、カルバモイル、C1〜C4アルキルカルバモ イル又はジ(C1〜C4アルキル)カルバモイルにより置換されている、請求項1 から7のいずれかに記載の化合物。 9.式中のDが、未置換であるか、又はハロ、ニトロ、ヒドロキシ、シアノ、 C1〜C6アルキル、アミノ、C1〜C6アルコキシ又はカルバモイルにより置換さ れている、請求項1から8のいずれかに記載の化合物。 10.式中のR1は、カルボキシ、カルバモイル、テトラゾリル又は式:−C ONRaRal又は−CONHSO2Rb(ここで、Raは、請求項1中と同様に定義 され、Ralは、水素、ヒドロキシ、場合により置換された:C1〜C6アルキル、 C2〜C6アルケニル、C2 〜C6アルキニル、シクロプロピルC1〜C4アルキル、シクロブチルC1〜アル キル、シクロペンチルC1〜C4アルキル、シクロヘキシルC1〜C4アルキル、ピ リジルC1〜C4アルキル、ピリミジルC1〜C4アルキル、ピラジニルC1〜C4ア ルキル、フリルC1〜C4アルキル、ピリダジニルC1〜C4アルキル、テトラゾリ ルC1〜C4アルキル、ピロリジニルC1〜C4アルキル、モルホリニルC1〜C4ア ルキル、イミダゾリウムC1〜C4アルキル、N−メチルイミダゾリウムC1〜C4 アルキル、ピリジニウムC1〜C4アルキル、ピリジル、ピリミジル、ピラジニル 、ピリダジニル、N−メチルピリミジニウム、N−メチルイミダゾリル、ピリジ ニウム、ピリミジニウム、テトラゾリル、フェニル、シクロプロピル、シクロブ チル、シクロペンチル、シクロヘキシル、シクロペンテニル、シクロヘキセニル 、シクロヘプテニル、シクロペンテニルC1〜C4アルキル、シクロヘキセニルC1 〜C4アルキル又はシクロヘプテニルC1〜C4アルキルであり、かつRbは、C1 〜C4アルキル(場合により、ヒドロキシ、ニトロ、シアノ、アミノ、C1〜C4 アルキルアミノ、ジ−C1〜C4アルキルアミノ、C1〜C4アルカノイルアミノ、 N−C1〜C4アルキル−N−C1〜C4アルコニルアミノ、カルバモイル、C1〜 C4アルキルカルバモイル、ジ−(C1〜C4アルキル)カルバモイル、ハロ、C1〜 C4アルコキシにより置換されている)又は場合に より置換された:フェニルC1〜C3アルキル、ピリジルC1〜C3アルキル、フェ ニル、チエニル、チアジアゾリル、オキサゾリル、イソオキサゾリル、ピラゾリ ル又は1,1−ジオキシドテトラヒドロチエニルである、請求項1から8のいず れかに記載の化合物。 11.式(IV): [式中、 R1及びR2は、請求項1中と同様に定義され、R5は、ハロ、ニトロ、ヒドロ キシ、アミノ、シアノ、C1〜C6アルキル、C1〜C6アルコキシ又はカルバモイ ルであり、nは、0又は1であり、R6は、ハロ、ニトロ、トリフルオロメチル 、シアノ、アミノ、C1〜C6アルコキシ、カルバモイル、C1〜C4アルキルカル バモイル、ジ(C1〜C4アルキル)カルバモイル、C1〜C4アルカノイルアミノ 、S(O)pC1〜C6アルキル、C1〜C4アルカンスルホンアミド、ベンゼンス ルホンアミド、C1〜C6アルカノイル、C1〜C4アルコキシアミノC1〜C4アル キル又はヒドロキシイミノC1〜C4アルキルであり、かつBは、フェニル、チエ ニル、ピリダジニル、ピリジル又はチアゾリルである]の化合物。 12.例1〜30及び第1〜1g、2〜2f、3〜3a、4及び5〜5b表中 に包含される、請求項1に記載の化合物。 13. 2−[N−(2−ベンジルオキシ−5−ブロモベンジル)−N−メチル アミノ]ピリジン−5−カルボン酸; 2−[N−(2−ベンジルオキシ−5−ブロモベンジル)−N−エチルアミノ]ピ リジン−5−カルボン酸; N−(3−ピリジルメチル)−2−[N−(2−ベンジルオキシ−5−ブロモベン ジル)−N−エチルアミノ]ピリジン−5−カルボキサミド; 2−[N−(2−ベンジルオキシ−5−ブロモベンジル)−N−プロプ−2−イ ン−1−イル) アミノ]ピリジン−5−カルボン酸; 2−[N−(2−ベンジルオキシ−5−ブロモベンジル)−N−アリルアミノ]ピ リジン−5−カルボン酸; 2−[N−(2−ベンジルオキシ−5−クロロベンジル)−N−エチルアミノ]ピ リジン−5−カルボン酸; 2−[N−(2−ベンジルオキシ−5−メチルチオベンジル)−N−エチルアミ ノ]ピリジン−5−カルボン酸; 2−[N−(2−(4−メチルフェニルメトキシ)−5−ブロモベンジル)−N− エチルアミノ]ピリジン−5−カルボン酸; 2−[N−(2−(3−クロロフェニルメトキシ)−5 −ブロモベンジル)−N−エチルアミノ]ピリジン−5−カルボン酸; 2−[N−(2−(4−クロロフェニルメトキシ)−5−ブロモベンジル)−N− エチルアミノ]ピリジン−5−カルボン酸; 2−[N−(2−チエニルメトキシ−5−ブロモベンジル)−N−エチルアミノ] ピリジン−5−カルボン酸; 6−[N−(2−ベンジルオキシ−5−ブロモベンジル)−N−エチルアミノ]− 2−エトキシピリジン−5−カルボン酸; 2−[N−(2−(4−ブロモベンジルオキシ)−5−ブロモベンジル)−N−エ チルアミノ]ピリジン−5−カルボン酸; 6−[N−(2−ベンジルオキシ−5−ブロモベンジル)−N−エチルアミノ]ピ リダジン−3−カルボン酸; 4−[N−(2−ベンジルオキシ−5−ニトロベンジル)−N−エチルアミノ]安 息香酸; N−ベンゼンスルホニル−5−[N−(2−ベンジルオキシ−5−ブロモベンジ ル)−N−エチルアミノ]チオフェン−2−カルボキサミド; N−プロピル−2−[N−(2−ベンジルオキシ−5−ブロモベンジル)−N− エチルアミノ]チアジアゾール−5−カルボキサミド; 5−[4−(N−(2−ベンジルオキシ−5−ブロモベンジル)−N−エチルアミ ノ)フェニル]テトラゾール; N−ベンゼンスルホニル−2−[N−(2−ベンジルオキシ−5−ブロモベンジ ル)−N−エチルアミノ]チアジアゾール−5−カルボキサミド; N−(3−ピリジルメチル)−2−[N−(2−ベンジルオキシ−5−ブロモベン ジル)−N−エチルアミノ]チアジアゾール−5−カルボキサミド; N−プロピル−6−[N−(2−ベンジルオキシ−5−ブロモベンジル)−N− エチルアミノ]ピリダジン−3−カルボキサミド; 4−[N−(2−ベンジルオキシ−4−ブロモベンジル)−N−エチルアミノ]安 息香酸; 4−[N−(2−ベンジルオキシ−5−ブロモベンジル)−N−エチルアミノ]安 息香酸; N−(ベンゼンスルホニル)−2−[N−(2−ベンジルオキシ−5−ブロモベン ジル)−N−エチルアミノ]ピリジン−5−カルボキサミド; N−(プロパンスルホニル)−2−[N−(2−ベンジルオキシ−5−ブロモベン ジル)−N−エチルアミノ]ピリジン−5−カルボキサミド; N−(2−ヒドロキシエタンスルホニル)−2−[N−(2−ベンジルオキシ−5 −ブロモベンジル)−N−エチルアミノ]ピリジン−5−カルボキサミド; N−(ベンゼンスルホニル)−6−[N−(2−ベンジルオキシ−5−ブロモベン ジル)−N−エチルアミノ]ピリダジン−3−カルボキサミド; N−(ベンジルスルホニル)−2−[N−(2−ベンジルオキシ−5−メタンスル ホニルベンジル)−N−エチルアミノ]ピリジン−5−カルボキサミド; N−(5−メチルカルバモイル−1,3,4−チアジアゾール−2−スルホニ ル)−2−[N−(2−ベンジルオキシ−5−ブロモベンジル)−N−エチルアミノ ]ピリジン−5−カルボキサミド; N−(3,5−ジメチルイソオキサゾール−4−スルホニル)−6−[N−(2− ベンジルオキシ−5−ブロモベンジル)−N−エチルアミノ]ピリダジン−3−カ ルボキサミド; N−(ベンゼンスルホニル)−4−[N−(2−ベンジルオキシ−5−メタンスル ホニルベンジル)−N−エチルアミノ]ベンゼンカルボキサミド; N−(3−ヒドロキシ−1−カルボキシプロプ−2−イル)−2−[N−(2−ベ ンジルオキシ−5−ブロモベンジル)−N−エチルアミノ]ピリジン−5−カルボ キサミド; N−(1−カルボキシペント−2−イル)−2−[N−(2−ベンジルオキシ−5 −ブロモベンジル)−N−エチルアミノ]ピリジン−5−カルボキサミド; N−ベンジル−2−[N−(2−ベンジルオキシ−5 −ブロモベンジル)−N−エチルアミノ]ピリジン−5−カルボキサミド; N−(テトラゾール−5−イルメチル)−2−[N−(2−ベンジルオキシ−5− ブロモベンジル)−N−エチルアミノ]ピリジン−5−カルボキサミド; 2−[N−(2−ベンジルオキシ−5−ブロモベンジル)−N−エチルアミノ]オ キサゾール−4−カルボン酸; 4−[N−(2−ベンジルオキシ−4−メチルベンジル)−N−エチルアミノ]安 息香酸; N−(2−ヒドロキシエチル)−2−[N−(2−ベンジルオキシ−5−ブロモベ ンジル)−N−エチルアミノ]チアゾール−4−カルボキサミド; N−(2−(S)−ヒドロキシプロプ−1−イル)−2−[N−(2−ベンジルオキ シ)−5−ブロモベンジル)−N−エチルアミノ]チアゾール−5−カルボキサミ ド; N−(2−ヒドロキシエチル)−2−[N−(2−ベンジルオキシ−5−ブロモベ ンジル)−N−エチルアミノ]チアゾール−5−カルボキサミド; 5−[3−(N−(2−ベンジルオキシ−5−ブロモベンジル)−N−エチルアミ ノ)フェニル]テトラゾール; 2−[N−(2−ベンジルオキシベンジル)−N−エチルアミノ]ピリジン−5− カルボン酸; N−(ベンゼンスルホニル)−4−[N−(3−ベンジルオキシ−2−チエニルメ チル)−N−エチルアミノ]ベンゼンカルボキサミド; N−プロピル−4−[N−(3−ベンジルオキシ−2−チエニルメチル)−N− エチルアミノ]ベンゼンカルボキサミド; 4−[N−(2−ベンジルオキシ−5−ブロモベンジル)−N−エチルアミノ]− 3−エトキシ安息香酸; 4−[N−(2−ベンジルオキシ−2−チエニルメチル)−N−エチルアミノ]安 息香酸; 4−[N−(2−ベンジルオキシ−5−ブロモベンジル)−N−メチルアミノ]安 息香酸; N−(3−ピリジルメチル)−4−[N−(2−ベンジルオキシベンジル)−N− エチルアミノ]ベンゼンカルボキサミド; 5−[6−(N−(2−ベンジルオキシ−5−ブロモベンジル)−N−エチルアミ ノ)−3−ピリダジン]テトラゾール; 5−[N−(2−ベンジルオキシ−5−ブロモベンジル)−N−エチルアミノ]ピ ラジン−2−カルボン酸;又は N−(3,5−ジメチルイソオキサゾール−4−イルスルホニル)−2−[N−( 2−ベンジルオキシ−5−ブロモベンジル)−N−エチルアミノ]ピリジン−5− カルボキサミド; 又はこれらの薬剤的に容認可能な塩又は生体内で加水分解可能なエステル又はア ミドである、請求項1に記載の化合物。 14.請求項1から13のいずれかに記載の化合物及び薬剤学的に認容可能な キャリヤを有する、薬剤組成物。 15.疼痛を寛解する方法において、式(I)の化合物を、それが必要な患者 に投与することを特徴とする、疼痛を寛解する方法。 16.請求項1に記載の化合物の製法において、式(VI): [式中のR7は、請求項1中で定義されたR1であるか、又は保護されたR1であ り、R8は、請求項1中で定義されたR2であるか、又は保護されたR2であり、 R3、R4、A、B及びDは、請求項1中と同様に定義され;かついくつかの場合 による置換基は、場合により保護され、かつ少なくとも1つの保護基が存在する ]の化合物を脱保護し、かつその後更に、必要な場合には: i)薬剤学的に認容可能な塩を形成する; ii)生体内で加水分解可能なエステル又はアミドを形成する; iii)場合による置換基を、その他の場合による置換基に変換することから なることを特徴とする、請求項1に記載の化合物の製法。 17.請求項1に記載の化合物又は請求項16中で定義されているような式( VI)の化合物の製法において、 a)式(VII): [式中、A、B、D、R3、R4、R7及びR8は、請求項16中と同様に定義され る]の化合物を還元させる; b)Bが、活性複素環であり、かつR8が、水素又はC1〜C6アルキルである 場合には、式(IX)の化合物を、式(X): [式中、A、B、D、R3、R4及びR7は、請求項16中と同様に定義され、かつ Xは、脱離基である]の化合物と反応させる; c)式(VIII)の化合物と式(XI)の化合物 [式中、A、B、D、R3及びR4は、請求項16中と同様に定義され、かつX1は 、脱離基である]とを反応させる; d)式(XIII): [式中、A、B、D、R3、R4及びR8は、請求項16中と同様に定義され、かつ R10は、R7の前駆体である]の化合物を、式(I)又は(VI)の化合物に変換 する; e)R8が、水素以外である場合には、式:R8X2の化合物を、式(XIV) : [式中、A、B、D、R3、R4及びR7は、請求項16中と同様に定義され、かつ X2は、脱離基である]の化合物と反応させる; f)式(XV)の化合物を、式(XVI): [式中、R3、R4、R7、A、B及びDは、請求項16中と同様に定義され、かつ R11は、離脱可能な活性基である]の化合物と反応させる;又は g)式(XVII)の化合物を、式(XVIII) の化合物: [式中、R3、R4、R7、A、B及びDは、請求項16中と同様に定義され、かつ R12は、脱離基であり、かつR13は、活性基である]と反応させる; かつ、その後、必要な場合には: i)いくつかの保護基を除去する; ii)薬剤的に認容可能な塩を形成する; iii)生体内で加水分解可能なエステル又はアミドを形成する; iv)場合による置換基を、他の場合による置換基に変換することからなるこ とを特徴とする、請求項1に記載の化合物又は請求項16中で定義されているよ うな式(VI)の化合物の製法。 18.請求項17に定義されているような式(XIII)の化合物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9414924.2 | 1994-07-25 | ||
GB9414924A GB9414924D0 (en) | 1994-07-25 | 1994-07-25 | Aromatic compounds |
GB9501288.6 | 1995-01-24 | ||
GBGB9501288.6A GB9501288D0 (en) | 1995-01-24 | 1995-01-24 | Aromatic compounds |
PCT/GB1995/001728 WO1996003380A1 (en) | 1994-07-25 | 1995-07-21 | Aromatic amino ethers as pain relieving agents |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10503487A true JPH10503487A (ja) | 1998-03-31 |
Family
ID=26305334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8505573A Ceased JPH10503487A (ja) | 1994-07-25 | 1995-07-21 | 疼痛寛解剤としての芳香族アミノエーテル |
Country Status (28)
Country | Link |
---|---|
US (1) | US5843942A (ja) |
EP (1) | EP0773930B1 (ja) |
JP (1) | JPH10503487A (ja) |
KR (1) | KR970704690A (ja) |
CN (2) | CN1085663C (ja) |
AT (1) | ATE196898T1 (ja) |
AU (1) | AU688541B2 (ja) |
BG (1) | BG101259A (ja) |
BR (1) | BR9508335A (ja) |
CA (1) | CA2192088A1 (ja) |
CZ (1) | CZ22097A3 (ja) |
DE (1) | DE69519099T2 (ja) |
DK (1) | DK0773930T3 (ja) |
EE (1) | EE9700016A (ja) |
ES (1) | ES2150577T3 (ja) |
FI (1) | FI116219B (ja) |
GB (1) | GB9514160D0 (ja) |
GR (1) | GR3034603T3 (ja) |
HU (1) | HUT76606A (ja) |
IL (1) | IL114705A0 (ja) |
MX (1) | MX9606541A (ja) |
NO (1) | NO308032B1 (ja) |
NZ (1) | NZ289905A (ja) |
PL (1) | PL318283A1 (ja) |
PT (1) | PT773930E (ja) |
SK (1) | SK10197A3 (ja) |
TW (1) | TW411328B (ja) |
WO (1) | WO1996003380A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002537233A (ja) * | 1999-02-17 | 2002-11-05 | アストラゼネカ アクチボラグ | 治療剤 |
WO2008023783A1 (fr) * | 2006-08-25 | 2008-02-28 | Asahi Kasei Pharma Corporation | Composé amine |
JP2010535209A (ja) * | 2007-08-03 | 2010-11-18 | エフ.ホフマン−ラ ロシュ アーゲー | Taar1リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体 |
JP2015523369A (ja) * | 2012-07-06 | 2015-08-13 | ジェネンテック, インコーポレイテッド | N置換ベンズアミド及びその使用方法 |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9514160D0 (en) * | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
GB9417532D0 (en) * | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
GB9420557D0 (en) * | 1994-10-12 | 1994-11-30 | Zeneca Ltd | Aromatic compounds |
TW502026B (en) | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
TW434240B (en) * | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
EP0752421B1 (en) * | 1995-07-07 | 2005-10-12 | AstraZeneca AB | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists |
JP3445689B2 (ja) * | 1995-07-11 | 2003-09-08 | 新日本石油株式会社 | 液晶性光学フィルムおよび液晶性光学フィルムから成る液晶表示素子用補償フィルム並びに該補償フィルムを備えた液晶表示装置 |
TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
EP1007037A4 (en) * | 1997-06-26 | 2004-10-06 | Lilly Co Eli | ANTITHROMBOTIC AGENTS |
US6242474B1 (en) | 1997-06-27 | 2001-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Aromatic ring derivatives |
EP1216238B1 (en) * | 1999-09-14 | 2004-02-18 | Merck Frosst Canada & Co. | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
US6485740B1 (en) * | 2000-03-14 | 2002-11-26 | Yutoku Pharmaceutical Ind., Co., Ltd. | Transdermal methotrexate preparations |
AU9458401A (en) * | 2000-09-20 | 2002-04-02 | Ortho Mcneil Pharm Inc | Pyrazine derivatives as modulators of tyrosine kinases |
SE0100873D0 (sv) * | 2001-03-13 | 2001-03-13 | Astrazeneca Ab | Method of treatment |
US6825221B2 (en) | 2001-10-18 | 2004-11-30 | Allergan, Inc. | Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
CA2463102C (en) | 2001-10-23 | 2011-05-10 | Applied Research Systems Ars Holding N.V. | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors |
CA2469075C (en) | 2001-12-20 | 2011-09-13 | Applied Research Systems Ars Holding N.V. | Pyrrolidine derivatives as prostaglandin modulators |
US7419999B2 (en) | 2002-06-10 | 2008-09-02 | Applied Research Systems Ars Holding N.V. | Gamma lactams as prostaglandin agonists and use thereof |
US7262194B2 (en) * | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
DE60335957D1 (de) | 2002-10-08 | 2011-03-17 | Rinat Neuroscience Corp | Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen |
AU2003304238A1 (en) * | 2002-10-08 | 2005-01-13 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
PT1575517E (pt) | 2002-12-24 | 2012-05-28 | Rinat Neuroscience Corp | Anticorpos anti-ngf e métodos de utilização dos mesmos |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
SE0300457D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
SE0300458D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
CA2516454A1 (en) | 2003-02-19 | 2004-09-02 | Rinat Neuroscience Corp. | Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
SE0300456D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
EP1603858A2 (en) | 2003-03-11 | 2005-12-14 | NeuroSearch A/S | Kcnq channel modulating compounds and their pharmaceutical use |
WO2005041988A1 (en) * | 2003-10-22 | 2005-05-12 | University Of Florida | Method and composition for pain amelioration |
WO2005047249A1 (en) * | 2003-11-10 | 2005-05-26 | Schering Aktiengesellschaft | Benzylether amine compounds useful as ccr-5 antagonists |
WO2005087710A1 (ja) * | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
KR20060135060A (ko) | 2004-04-07 | 2006-12-28 | 리나트 뉴로사이언스 코퍼레이션 | 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법 |
JP5128954B2 (ja) | 2004-12-06 | 2013-01-23 | メルク セローノ ソシエテ アノニム | Dp1受容体アゴニストとして使用されるピロリジン−2−オン誘導体 |
EA200701324A1 (ru) | 2004-12-23 | 2007-10-26 | Глэксо Груп Лимитед | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина |
US20060160905A1 (en) * | 2005-01-18 | 2006-07-20 | Bergeron Raymond J Jr | Compositions and methods for inhibiting pain |
GB0508463D0 (en) * | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
US7610994B2 (en) * | 2005-05-13 | 2009-11-03 | Draka Elevator Products | Elevator compensating cable having a selected loop radius and associated system and method |
US20070066638A1 (en) * | 2005-09-16 | 2007-03-22 | Cun-Jian Dong | Ryanodine receptor blockers for treating pain |
BRPI0807942A2 (pt) | 2007-02-16 | 2014-07-01 | Ono Pharmaceutical Co | Agente terapêutico para distúrbio de excreção urinária |
CA2680366C (en) | 2007-03-09 | 2016-06-21 | University Health Network | Inhibitors of carnitine palmitoyltransferase and treating cancer |
WO2009015485A1 (en) | 2007-08-01 | 2009-02-05 | University Health Network | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer |
SI3333188T1 (sl) | 2010-08-19 | 2022-04-29 | Zoetis Belgium S.A. | Protitelesa proti NGF in njihova uporaba |
WO2013184871A1 (en) | 2012-06-06 | 2013-12-12 | Zoetis Llc | Caninized anti-ngf antibodies and methods thereof |
EP4159717A1 (en) | 2014-10-06 | 2023-04-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2017173274A1 (en) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
PT3519401T (pt) | 2016-09-30 | 2021-12-27 | Vertex Pharma | Modulador de regulador de condutância transmembranar de fibrose quística, composições farmacêuticas, métodos de tratamento e processo para fazer o modulador |
SI3551622T1 (sl) | 2016-12-09 | 2021-02-26 | Vertex Pharmaceuticals Incorporated | Modulatorji regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in postopek izdelave modulatorja |
WO2018227049A1 (en) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
AU2018309043B2 (en) | 2017-08-02 | 2022-03-31 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
MA51039A (fr) | 2017-12-08 | 2020-10-14 | Vertex Pharma | Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
WO2019177690A1 (en) | 2018-03-12 | 2019-09-19 | Zoetis Services Llc | Anti-ngf antibodies and methods thereof |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1543519B1 (de) * | 1966-06-16 | 1971-04-15 | Degussa | Verfahren zur Herstellung von p-Aminobenzoesaeureaniliden |
US3657430A (en) * | 1969-06-25 | 1972-04-18 | Merck & Co Inc | Composition and methods for treating inflammation |
US3632760A (en) * | 1969-06-25 | 1972-01-04 | Merck & Co Inc | Treatment of inflammation |
US4350822A (en) * | 1975-03-12 | 1982-09-21 | American Cyanamid Company | Antilipidemicpara-[aryl(alkyl or alkenyl)amino]benzoic acid derivatives |
AU510758B2 (en) * | 1976-01-19 | 1980-07-10 | The Dow Chemical Company | P-benzylaminobenzoic acids |
GB1576007A (en) * | 1976-02-11 | 1980-10-01 | Beecham Group Ltd | Hypolipidaemic compositions |
EP0000816A1 (en) * | 1977-08-06 | 1979-02-21 | Beecham Group Plc | Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them |
US4152452A (en) * | 1977-10-06 | 1979-05-01 | William H. Rorer, Inc. | Method of topically treating inflammation |
US4277496A (en) * | 1979-06-04 | 1981-07-07 | Laboratorios Bago S.A. | Methods of treating mammals suffering from inflammation and pain |
US4578390A (en) * | 1981-12-14 | 1986-03-25 | Merck & Co., Inc. | Hydroxybenzylamino derivatives as anti-inflammatory agents |
CA1193598A (en) * | 1982-05-06 | 1985-09-17 | Rafael Foguet | 2-amino-benzoic acid derivatives and processes for their production |
GB8320699D0 (en) * | 1983-08-01 | 1983-09-01 | Wellcome Found | Ethylenediamines |
US4614617A (en) * | 1985-02-25 | 1986-09-30 | G. D. Searle & Co. | Intermediates for 8-chlorodibenz[(b,f)][1,4]oxazepine-10(11H)-carboxylic acid, 2-(sulfinyl- and sulfonyl-containing acyl)hydrazides |
US4839369A (en) * | 1985-04-16 | 1989-06-13 | Rorer Pharmaceutical Corporation | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments |
US4892947A (en) * | 1985-04-27 | 1990-01-09 | Nissan Chemical Industries Ltd. | 3(2H)Pyridazinone, process for its preparation and anti-allergic agent containing it |
US4704386A (en) * | 1985-08-29 | 1987-11-03 | G. D. Searle & Co. | 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides |
DE3903989A1 (de) * | 1989-02-10 | 1990-09-20 | Basf Ag | Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika |
EP0482208B1 (en) * | 1990-04-25 | 2000-07-19 | Nissan Chemical Industries Ltd. | Pyridazinone derivative |
IL99246A0 (en) * | 1990-09-10 | 1992-07-15 | Abbott Lab | Angiotensin ii receptor antagonists and pharmaceutical compositions containing them |
GB9021813D0 (en) * | 1990-10-08 | 1990-11-21 | Ici Plc | Tricyclic heterocycles |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
CA2102780C (en) * | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
GB9120640D0 (en) * | 1991-09-27 | 1991-11-06 | Ici Plc | Tricyclic heterocycles |
ATE167861T1 (de) * | 1992-09-14 | 1998-07-15 | Takeda Chemical Industries Ltd | 1,2,4-oxadiazolyl oder 1,2,4-thiadiazolyl- derivate als angiotensin ii antagonisten |
US5324743A (en) * | 1992-12-10 | 1994-06-28 | Eli Lilly And Company | Leukotriene B4 antagonists |
DE4241632A1 (de) * | 1992-12-10 | 1994-06-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US5420270A (en) * | 1993-10-07 | 1995-05-30 | G. D. Searle & Co. | Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
TW326041B (en) * | 1993-12-16 | 1998-02-01 | Nippon Nouyaku Kk | Pyridazinone derivatives, their production process and their use for inhibition of platelet aggregation |
US5576335A (en) * | 1994-02-01 | 1996-11-19 | Nisshin Flour Milling Co., Ltd. | Urea derivatives and their use as ACAT inhibitors |
US5441950A (en) * | 1994-06-09 | 1995-08-15 | G. D. Searle & Co. | Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, pharmaceutical compositions and methods of use |
GB9514160D0 (en) * | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
GB9417532D0 (en) * | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
GB9420557D0 (en) * | 1994-10-12 | 1994-11-30 | Zeneca Ltd | Aromatic compounds |
TW502026B (en) * | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
TW434240B (en) * | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
EP0752421B1 (en) * | 1995-07-07 | 2005-10-12 | AstraZeneca AB | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists |
-
1995
- 1995-07-11 GB GBGB9514160.2A patent/GB9514160D0/en active Pending
- 1995-07-21 HU HU9603338A patent/HUT76606A/hu unknown
- 1995-07-21 PL PL95318283A patent/PL318283A1/xx unknown
- 1995-07-21 CN CN95194340A patent/CN1085663C/zh not_active Expired - Fee Related
- 1995-07-21 MX MX9606541A patent/MX9606541A/es not_active IP Right Cessation
- 1995-07-21 AU AU29883/95A patent/AU688541B2/en not_active Ceased
- 1995-07-21 JP JP8505573A patent/JPH10503487A/ja not_active Ceased
- 1995-07-21 EE EE9700016A patent/EE9700016A/xx unknown
- 1995-07-21 US US08/776,275 patent/US5843942A/en not_active Expired - Fee Related
- 1995-07-21 NZ NZ289905A patent/NZ289905A/en unknown
- 1995-07-21 CA CA002192088A patent/CA2192088A1/en not_active Abandoned
- 1995-07-21 AT AT95925943T patent/ATE196898T1/de not_active IP Right Cessation
- 1995-07-21 KR KR1019970700434A patent/KR970704690A/ko not_active Application Discontinuation
- 1995-07-21 DE DE69519099T patent/DE69519099T2/de not_active Expired - Fee Related
- 1995-07-21 PT PT95925943T patent/PT773930E/pt unknown
- 1995-07-21 SK SK101-97A patent/SK10197A3/sk unknown
- 1995-07-21 CZ CZ97220A patent/CZ22097A3/cs unknown
- 1995-07-21 EP EP95925943A patent/EP0773930B1/en not_active Expired - Lifetime
- 1995-07-21 BR BR9508335A patent/BR9508335A/pt not_active Application Discontinuation
- 1995-07-21 DK DK95925943T patent/DK0773930T3/da active
- 1995-07-21 WO PCT/GB1995/001728 patent/WO1996003380A1/en active IP Right Grant
- 1995-07-21 ES ES95925943T patent/ES2150577T3/es not_active Expired - Lifetime
- 1995-07-22 TW TW084107606A patent/TW411328B/zh not_active IP Right Cessation
- 1995-07-24 IL IL11470595A patent/IL114705A0/xx unknown
-
1997
- 1997-01-22 FI FI970261A patent/FI116219B/fi not_active IP Right Cessation
- 1997-01-24 NO NO970314A patent/NO308032B1/no unknown
- 1997-02-25 BG BG101259A patent/BG101259A/xx unknown
-
2000
- 2000-03-10 CN CN00104017A patent/CN1286254A/zh active Pending
- 2000-10-12 GR GR20000402119T patent/GR3034603T3/el not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002537233A (ja) * | 1999-02-17 | 2002-11-05 | アストラゼネカ アクチボラグ | 治療剤 |
WO2008023783A1 (fr) * | 2006-08-25 | 2008-02-28 | Asahi Kasei Pharma Corporation | Composé amine |
JP2010535209A (ja) * | 2007-08-03 | 2010-11-18 | エフ.ホフマン−ラ ロシュ アーゲー | Taar1リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体 |
JP2015523369A (ja) * | 2012-07-06 | 2015-08-13 | ジェネンテック, インコーポレイテッド | N置換ベンズアミド及びその使用方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10503487A (ja) | 疼痛寛解剤としての芳香族アミノエーテル | |
US6365603B1 (en) | Aromatic compounds and pharmaceutical compositions containing them | |
RU2198878C2 (ru) | Ароматические соединения и содержащие их фармацевтические композиции | |
US6787562B2 (en) | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | |
RU2182574C2 (ru) | Ароматические соединения и содержащие их фармацевтические композиции |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20031212 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20031216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060509 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060726 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061106 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070130 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20070522 |